Program
abemaciclib
Also written as “Abemaciclib”, “LY2835219” and “Abemaciclib Tablet (Test Formulation)”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Neoplasm Metastasis · Sarcoma, Ewing, led by 2 companies.
Drug pageAbemaciclib: every studyAll 156 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 4814 open or running | phase 4since Jun 12, 2019 | Jul 12, 2011 | Nov 2026phase 1 · NCT07818967 |
| Hoffmann-La Roche | 10 open or running | phase 2since Sep 11, 2017 | Sep 11, 2017 | none ahead |
Also a collaborator on its studies: Bayer and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2017First study: phase 2 study in Breast NeoplasmsFirst studyNCT03280563 · 144 enrolled · United States, Israel, South Korea
TargetBeta
“The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| palbociclibrule | Pfizer | phase 4 | 36 |
| trilaciclibrule | Pharmacosmos | phase 4 | 14 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
Studies
The one study Hoffmann-La Roche leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03280563Breast Neoplasms · United States, Israel, South Korea | 2 | Completed | Sep 26, 2024 | 144 |
How it is read
Names in the registry
- “Abemaciclib”, 41 entries
- “LY2835219”, 5 entries
- “Abemaciclib Tablet (Test Formulation)”, 2 entries
- “Abemaciclib Tablet (Reference Formulation)”, 1 entry
- “Abemaciclib Oral Granules (Test Formulation)”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Prostatic Neoplasms, 4 studies
- Neoplasm Metastasis, 4 studies
- Sarcoma, Ewing, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.